COVID-19 Vaccination as a Precipitating Factor in Cutaneous Lupus Erythematosus with Lupus Nephritis: A Clinical Case Report
Main Article Content
Keywords
Cutaneous lupus erythematosus, Moderna vaccine, COVID-19 vaccination, lupus nephritis
Abstract
The advent of the COVID-19 vaccine has improved global mortality, but recent literature suggests that COVID-19 vaccinations may induce or exacerbate autoimmune rheumatic diseases. Here, we present a 64-year-old woman with a history of Evans syndrome, pernicious anemia, and positive antinuclear antibody (ANA) who developed systemic lupus erythematosus (LE) presenting with cutaneous involvement following her first Moderna COVID-19 vaccine dose. She presented with a pruritic rash, malaise, and paresthesia ten days after vaccination. Clinical examination revealed erythematous, scaly, annular plaques on her face, ears, upper extremities, and chest, hand edema, and a palatal erosion. Laboratory findings included an elevated ANA titer (1:640), positive anti-RNP and anti-Ro antibodies, hematuria and proteinuria. This contrasted with previous laboratory results from 2019, where her ANA titer was higher at 1:2560, with anti-RNP elevated at 358 and anti-Ro at 252. Skin biopsy confirmed cutaneous LE and renal biopsy confirmed membranous lupus nephritis. Treatment included hydroxychloroquine, mycophenolate mofetil, prednisone, clobetasol ointment, and triamcinolone ointment, with subsequent improvement. Although rare, COVID-19 vaccination should be considered as a potential trigger for LE, particularly in patients with predisposition to autoimmune disease. Vaccination against COVID-19 should still be encouraged among patients with autoimmune rheumatic diseases, preferably during remission and before the initiation of disease-modifying antirheumatic drugs.
References
2. Kreuter, A., Licciardi-Fernandez, M. J., Burmann, S. N., Burkert, B., Oellig, F., & Michalowitz, A. L. (2022). Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA-based or adenoviral vector-based SARS-CoV-2 vaccination. Clinical and experimental dermatology, 47(1), 161–163. https://doi.org/10.1111/ced.14858
3. Gambichler, T., Boms, S., Susok, L., Dickel, H., Finis, C., Abu Rached, N., Barras, M., Stücker, M., & Kasakovski, D. (2022). Cutaneous findings following COVID-19 vaccination: review of world literature and own experience. Journal of the European Academy of Dermatology and Venereology : JEADV, 36(2), 172–180. https://doi.org/10.1111/jdv.17744
4. Joudeh, A. I., Lutf, A. Q., Mahdi, S., & Tran, G. (2023). Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review. Vaccine, 41(26), 3801–3812. https://doi.org/10.1016/j.vaccine.2023.05.048
5. Chen, Y., Xu, Z., Wang, P., Li, X. M., Shuai, Z. W., Ye, D. Q., & Pan, H. F. (2022). New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology, 165(4), 386–401. https://doi.org/10.1111/imm.13443
6. Curtis, J. R., Johnson, S. R., Anthony, D. D., Arasaratnam, R. J., Baden, L. R., Bass, A. R., Calabrese, C., Gravallese, E. M., Harpaz, R., Kroger, A., Sadun, R. E., Turner, A. S., Williams, E. A., & Mikuls, T. R. (2023). American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5. Arthritis & rheumatology (Hoboken, N.J.), 75(1), E1–E16. https://doi.org/10.1002/art.42372
7. Wither, J., Johnson, S. R., Liu, T., Noamani, B., Bonilla, D., Lisnevskaia, L., Silverman, E., Bookman, A., & Landolt-Marticorena, C. (2017). Presence of an interferon signature in individuals who are anti-nuclear antibody positive lacking a systemic autoimmune rheumatic disease diagnosis. Arthritis research & therapy, 19(1), 41. https://doi.org/10.1186/s13075-017-1243-y
8. Teijaro, J. R., & Farber, D. L. (2021). COVID-19 vaccines: modes of immune activation and future challenges. Nature reviews. Immunology, 21(4), 195–197. https://doi.org/10.1038/s41577-021-00526-x
9. Gisondi, P., Bellinato, F., & Girolomoni, G. (2022). Skin adverse reactions to Sars-CoV-2 vaccination: a relevant responsibility issue for dermatologists. Journal of the European Academy of Dermatology and Venereology : JEADV, 36(2), 165–166. https://doi.org/10.1111/jdv.17854
10. Soy, M., Keser, G., Atagunduz, P., Mutlu, M. Y., Gunduz, A., Koybaşi, G., & Bes, C. (2021). A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review. Clinical rheumatology, 40(9), 3533–3545. https://doi.org/10.1007/s10067-021-05700-z
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.